

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses

Received: 12 July 2023

Accepted: 25 March 2024

Published online: 23 April 2024

 Check for updates

A list of authors and their affiliations appears at the end of the paper

Programmed death-1 (PD-1) inhibitors are approved for therapy of gynecologic cancers with DNA mismatch repair deficiency (dMMR), although predictors of response remain elusive. We conducted a single-arm phase 2 study of nivolumab in 35 patients with dMMR uterine or ovarian cancers. Co-primary endpoints included objective response rate (ORR) and progression-free survival at 24 weeks (PFS24). Secondary endpoints included overall survival (OS), disease control rate (DCR), duration of response (DOR) and safety. Exploratory endpoints included biomarkers and molecular correlates of response. The ORR was 58.8% (97.5% confidence interval (CI): 40.7–100%), and the PFS24 rate was 64.7% (97.5% one-sided CI: 46.5–100%), meeting the pre-specified endpoints. The DCR was 73.5% (95% CI: 55.6–87.1%). At the median follow-up of 42.1 months (range, 8.9–59.8 months), median OS was not reached. One-year OS rate was 79% (95% CI: 60.9–89.4%). Thirty-two patients (91%) had a treatment-related adverse event (TRAE), including arthralgia ($n = 10$, 29%), fatigue ($n = 10$, 29%), pain ($n = 10$, 29%) and pruritis ($n = 10$, 29%); most were grade 1 or grade 2. Ten patients (29%) reported a grade 3 or grade 4 TRAE; no grade 5 events occurred. Exploratory analyses show that the presence of dysfunctional ($CD8^+PD-1^+$) or terminally dysfunctional ($CD8^+PD-1^+TOX^+$) T cells and their interaction with programmed death ligand-1 ($PD-L1^+$) cells were independently associated with PFS24. PFS24 was associated with presence of *MEGF8* or *SETD1B* somatic mutations. This trial met its co-primary endpoints (ORR and PFS24) early, and our findings highlight several genetic and tumor microenvironment parameters associated with response to PD-1 blockade in dMMR cancers, generating rationale for their validation in larger cohorts. ClinicalTrials.gov identifier: [NCT03241745](https://clinicaltrials.gov/ct2/show/study/NCT03241745).

Endometrial cancer and ovarian cancer are among the most common and fatal malignancies for women in the United States, with an estimated 13,030 and 13,270 deaths, respectively, in 2023 (ref. 1). In patients with advanced or recurrent disease, the survival benefit with

single-agent chemotherapy or hormone therapy is modest at best^{2–4}. Work from The Cancer Genome Atlas (TCGA) has demonstrated that, within endometrial cancer, there are four distinct molecular subtypes: *POLE* ultramutated, microsatellite instability (MSI) hypermutated,

copy number-low and copy number-high⁵. These molecular subtypes are associated with progression-free survival (PFS) and overall survival (OS), with *POLR* ultramutated tumors having the best outcomes and copy number-high tumors having the worst. Approximately 30% to 35% of endometrial cancers are classified as MSI or DNA mismatch repair deficient (dMMR)^{5,6}. MSI leads to the accumulation of mismatches, insertions and deletions in repeat sequences of DNA—and, thus, a mutation burden approximately 10-fold greater than microsatellite stable (MSS) tumors. Although most common in endometrioid or clear cell histologies, a subset of ovarian cancers also demonstrates dMMR⁷. Based on findings from five single-arm studies that reported durable responses in approximately 50% of treated patients, pembrolizumab, an anti-programmed death-1 (PD-1) monoclonal antibody, was granted accelerated approval by the US Food and Drug Administration (FDA) as the first tissue-site-agnostic agent in patients with MSI-high (MSI-H) or dMMR cancers that progressed after prior treatment^{6,8–10}. Subsequently, dostarlimab was granted accelerated approval for patients with dMMR endometrial cancer who progressed on or after treatment with platinum-based chemotherapy¹¹. More recently, the randomized, placebo-controlled, phase 3 RUBY (ref. 12) and NRG-GY018 (ref. 13) studies demonstrated a PFS benefit with the addition of PD-1 blockade to platinum-based chemotherapy for patients with advanced or recurrent endometrial cancer; there was substantial benefit in the dMMR/MSI population.

Aside from the presence of dMMR, predictors of response to PD-1/programmed death ligand-1 (PD-L1) inhibition remain elusive. MSI can arise from somatic or germline mutations in MMR genes (that is, *MLH1*, *MSH2*, *MSH6* and *PMS2*) or hypermethylation of the *MLH1* promoter. It has been suggested that the etiology of dMMR (genetic versus epigenetic) is associated with distinct biology and may be predictive of response to immunotherapy in endometrial cancer^{14,15}, and mutations in *JAK1* and *B2M* are associated with resistance¹⁶. Several tumor microenvironment (TME) features, such as expression of PD-L1 (ref. 17) and presence of CD8⁺ T cells in tumors¹⁸, were demonstrated to be predictive of response to PD-1/PD-L1 inhibitors in some cancer types; however, their predictive value in dMMR gynecologic cancers is unknown. Emerging evidence in other cancer types indicates that T cell functional states, rather than absolute numbers, may serve as a stronger predictor of response to immune checkpoint blockade¹⁹. Specifically, upregulation of markers of T cell dysfunction/exhaustion, such as PD-1, is associated with tumor antigen reactivity. The transcription factor TOX was identified as a master regulator driving the molecular and epigenetic programs of T cell dysfunction/exhaustion in tumors²⁰. However, how these parameters predict response to PD-1 inhibition in patients with dMMR gynecologic cancers is unknown.

Here we report on a phase 2 study of nivolumab, a fully humanized monoclonal antibody to PD-1, in patients with dMMR/MSI-H advanced or recurrent endometrial or ovarian cancer (ClinicalTrials.gov identifier [NCT03241745](https://clinicaltrials.gov/ct2/show/study/NCT03241745)). We demonstrate that nivolumab is active in patients with dMMR gynecologic cancers, and we identify genomic and TME parameters predictive of response that may help guide patient selection for future trials.

Results

Study design

Eligible patients had recurrent endometrial cancer or a carcinosarcoma or an endometrioid or clear cell carcinoma that appeared to have originated in the ovary/fallopian tube or peritoneum and met one of the following criteria: (1) dMMR, as determined by loss of expression assessed by immunohistochemistry of one or more of the MMR proteins (*MSH2*, *MSH6*, *MLH1* and *PMS2*); (2) MSI-H, as determined by next-generation sequencing (NGS) using Memorial Sloan Kettering Cancer Center-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT; MSIsensor)^{21,22}; or (3) hypermutated tumors, defined as 20 or more non-synonymous somatic mutations on MSK-IMPACT.




Fig. 1 | CONSORT (Consolidated Standards of Reporting Trials) diagram showing the flow of patients and their disposition. CONSORT diagram. The trial was terminated as of 1 July 2022, and all remaining patients on therapy were transitioned to standard care.

The study protocol underwent two noteworthy amendments. Additional details about these amendments, patient selection and trial design are provided in the Methods section.

In total, 35 patients were enrolled in this study; the first patient consented on 27 September 2017 and the final patient on 24 May 2021. (Fig. 1). Patients received nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks until progressive disease or unacceptable toxicity. Baseline patient characteristics are reported in Table 1. The median age was 64 years (range, 36–87 years), and 77% of patients were White, 11% were Black and 6% were Asian. Most patients (83%) had endometrioid endometrial cancer. All enrolled patients were biologically female; gender information was not collected on the study.

Primary endpoint results

The co-primary endpoints were to define (1) the objective response rate (ORR) and (2) the PFS at 24 weeks (PFS₂₄). A total of 35 of a planned 40 patients were enrolled and treated. One patient was classified as non-evaluable due to progression of disease and death before the first scheduled follow-up assessment. The trial met its primary endpoint early, with 20 of 34 evaluable patients achieving an objective response by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; thus, it was closed early. In the evaluable cohort ($n = 34$), the ORR was 58.8% (97.5% confidence interval (CI): 40.7–100%), with seven complete responses and 13 partial responses (Fig. 2a,b and Extended Data Table 1). Objective responses were noted in both ovarian and endometrial cancers across histologic subtypes and grades and mechanisms of dMMR (*MLH1* hypermethylation, somatic mutation or germline mutation in an MMR gene) (Extended Data Table 2). Of note, one patient was enrolled based on partial *MLH1* loss by immunohistochemistry but was found to have MSS disease and low tumor mutational burden (TMB) on MSK-IMPACT testing, suggesting that she actually had MMR-proficient disease. This patient had progression of disease at her first follow-up

Table 1 | Demographics and baseline characteristics of patients with dMMR, MSI-H or hypermutated endometrial or ovarian cancer

Characteristic	
Age (median, range)	64 (36–87)
Ethnicity (n, %)	
Non-Hispanic	31 (89%)
Hispanic	3 (9%)
Ethnicity not known	1 (3%)
Race (n, %)	
White	27 (77%)
Black	4 (11%)
Asian	2 (6%)
Other/Unknown	2 (6%)
Stage at diagnosis (n, %)	
I	10 (29%)
II	6 (17%)
III	12 (34%)
IV	7 (20%)
Histology (n, %)	
Endometrioid FIGO G1	8 (23%)
Endometrioid FIGO G2	8 (23%)
Endometrioid FIGO G3	13 (37%)
Clear cell carcinoma	2 (6%)
Dedifferentiated/Undifferentiated	4 (11%)
Molecular subtype (n, %)	
Germline MMR mutation	5 (14%)
MLH1 promoter hypermethylation	23 (66%)
Other/Unknown ^a	7 (20%)
No. of prior lines of cytotoxic therapy (n, %)	
1	30 (86%)
2	4 (11%)
3	1 (3%)

^a Other molecular subtypes; see Supplementary Table 1 for more information. FIGO, International Federation of Gynecology and Obstetrics.

scan and came off study. PFS24 was a co-primary endpoint; in 34 evaluable patients, the PFS24 rate was 64.7% (97.5% one-sided CI: 46.5–100%), meeting the pre-specified endpoint of 50%.

Secondary endpoint results

Secondary endpoints included PFS, OS, duration of response (DOR), disease control rate (DCR) and safety. The DCR was 73.5% (95% CI: 55.6–87.1%) (Extended Data Table 1). Among the responders, with a median follow-up of 28 months (range, 2.5–42.5 months), the median DOR was not reached (Fig. 2a). At the time of data cutoff, with a median follow-up of 42.1 months (range, 8.9–59.8 months), the median PFS was 21.6 months (95% CI: 4.9–not evaluable (NE)), and the median OS was not reached; the 1-year OS rate was 79% (95% CI: 60.9–89.4%) (Fig. 2c,d).

All 35 patients were evaluated for adverse events (AEs) (Table 2 and Extended Data Table 3). Thirty-two patients (91%) had a treatment-related adverse event (TRAE) of any grade (Extended Data Tables 4 and 5). Among all 35 patients, the most common TRAEs were arthralgia ($n = 10$, 29%), fatigue ($n = 10$, 29%), pain ($n = 10$, 29%) and pruritis ($n = 10$, 29%) (Table 2). Ten patients (29%) reported a grade 3 or grade 4 TRAE, including immune-mediated toxicities such as

myocarditis ($n = 1$, 3%), optic neuritis ($n = 1$, 3%), hemolysis ($n = 1$, 3%) and type 1 diabetes ($n = 1$, 3%) (Extended Data Table 4); there were no grade 5 events. The patient who developed insulin-dependent diabetes remained on study after her blood sugars were stabilized. The patients who developed non-endocrine grade 3/4 events discontinued nivolumab therapy and were treated with steroids and other steroid-sparing immunosuppressive agents per published guidelines. In all patients, the events resolved with appropriate medical management.

Grade 3 myocarditis was diagnosed in one patient who presented for evaluation for fatigue and double vision 2 weeks after the first dose of nivolumab. An electrocardiogram (EKG) was performed, which recorded complete atrioventricular block with ventricular escape rhythm. She was admitted to an outside cardiac intensive care unit where she was treated with prednisone, mycophenolate mofetil and beta blocker; she did not require a permanent pacemaker. She had a concurrent diagnosis of grade 2 myasthenia gravis. Her EKG normalized, and her myasthenia gravis symptoms resolved, and she was able to be tapered off all immunosuppression.

TME analyses

We further explored the pre-treatment immune phenotype as an exploratory objective. Archival formalin-fixed paraffin-embedded (FFPE) tissue was available from 25 patients for evaluation by multiplexed immunofluorescence microscopy imaging. We stratified patients based on the co-primary endpoint of PFS24–13 who had PFS24 (clinical benefit) and 12 who did not (no clinical benefit). Segmentation was performed to isolate tumor and stromal compartments, and quantification of the relative percentages of cell populations and their functional states and interactions was performed in the tumor compartment (Fig. 3a)²³. Overall CD8⁺ T cell infiltration was associated with clinical benefit ($P = 0.026$) in contrast to tumor infiltration with regulatory T cells (FoxP3⁺) or CD8⁺/FoxP3 ratio, which were not (Fig. 3b). When focusing on CD8⁺ T cell functional states, we specifically assessed the expression of PD-1, a marker of chronic antigen stimulation and dysfunction that was demonstrated to enrich for tumor-specific T cells across a number of cancers^{24–27}, and TOX, a transcriptional master regulator responsible for terminal T cell dysfunction²⁰. Increases in both dysfunctional (CD8⁺PD-1⁺) and terminally dysfunctional (CD8⁺PD-1⁺TOX⁺) T cells were strongly associated with clinical benefit ($P = 0.006$ and $P = 0.001$, respectively), with a large proportion of the CD8⁺ T cell compartment being dysfunctional or terminally dysfunctional in the patients who benefited (Fig. 3c). Expression of PD-L1 was not associated with response, neither when looking at PD-L1 expression in Pax8⁺ tumor cells nor combined (tumor and immune cell) PD-L1 expression (Fig. 3d). Because PD-L1 expression is a dynamic marker upregulated in response to interferon-gamma (IFN- γ) secretion by CD8⁺ T cells, we hypothesized that upregulation of PD-L1 in proximity of CD8⁺ T cells or dysfunctional CD8⁺ T cells could serve as a surrogate marker of T cell activation (Fig. 3e and Extended Data Fig. 1). Tumors from patients with clinical benefit exhibited closer proximity between the CD8⁺PD-1⁺ cells and the nearest PD-L1⁺ cells, with a median distance of 52 μm versus 212 μm in patients without benefit (Extended Data Fig. 1). Based on the reported distance of T-cell-produced IFN- γ action on the neighboring cells estimated to be at 30–40 μm (ref. 28), we examined the interaction of PD-L1⁺ cells with CD8⁺ and CD8⁺PD-1⁺ T cells using 50 μm as a cutoff. Both interactions were strongly associated with clinical benefit (Fig. 3f,g). By the same analogy, the interaction of regulatory T cells with CD8⁺ and CD8⁺PD-1⁺ T cells was strongly associated with clinical benefit (Fig. 3h). Due to association of multiple variables with clinical benefit, as an additional post hoc analysis, we built a multiple logistic regression model based on the relative magnitude of difference for each parameter between those who did and did not benefit and the correlation between the parameters to identify a set of variables independently associated with clinical benefit. We found minimal correlation




Fig. 2 | Efficacy outcomes for patients. **a**, Swimmer plot depicting individual duration of treatment, response and clinical outcome at data cutoff ($n = 35$). **b**, Waterfall plot of best percentage tumor change from baseline ($n = 34$)

c, Kaplan–Meier graphical representation of PFS ($n = 35$). **d**, Kaplan–Meier graphical representation of OS ($n = 35$). CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

between the percentage of CD8⁺PD-1⁺TOX⁺ T cells out of the total CD8 population (parameter 1) and percentage of PD-L1⁺ cells within 50 μm of CD8⁺PD-1⁺ T cells (parameter 2) (Fig. 3i). Based on the magnitude of difference between these parameters in the two groups (Fig. 3c,g,j), bottom tertiles (41% for parameter 1 and 25.6% for parameter 2) were selected as cutoffs for each of the biomarkers to differentiate clinical benefit from no benefit (Fig. 3k). A receiver operating characteristic (ROC) curve was used to plot the sensitivity along the y axis and the ‘1-Specificity’ along the x axis for multivariate model prediction of clinical benefit as outcome, resulting in an area under the curve (AUC) of 0.897 ($P = 0.0007$), demonstrating a strong ability of these variables to predict immunotherapy outcomes in these patients (Fig. 3l).

Genomic analyses

As an exploratory objective, we correlated the somatic mutational burden with clinical benefit from nivolumab. Tumors from 33 of 34 evaluable patients were subjected to whole-exome sequencing. In the overall cohort, somatic mutations affecting the PI3K signaling pathway, including *PTEN* (76%) and *PIK3CA* (48%); the SWI/SNF chromatin-remodeling genes, including *ARID1A* (82%); the JAK/STAT signaling pathway, including *JAK1* (24%) and *CTNNB1* (15%); and the Hedgehog signaling pathway, including *MEGF8* (18%) and *PTCH1* (18%), were found (Fig. 4a and Extended Data Fig. 2). Ten cases (30%) harbored pathogenic somatic mutations affecting an MMR gene, including *MLH1*, *MSH2*, *MSH6* or *PMS2*. Whole-exome sequencing-based MSI analysis revealed that 79% (26 of 33) of endometrial/ovarian cancers were MSI-H, whereas seven endometrial cancers (21%) were MSS. Mutational signature analysis further showed that 79% (26 of 33) of tumors had a dominant mutational

Table 2 | TRAEs

Toxicity (selected TRAEs ^a)	Grade 1/2, n(%)	Grade 3/4, n(%)	Any grade, n(%)
Arthralgia	9 (26)	1 (3)	10 (29)
Diarrhea	7 (20)	0 (0)	7 (20)
Dyspnea	7 (20)	1 (3)	8 (23)
Fatigue	10 (29)	0 (0)	10 (29)
Gastrointestinal disorders	7 (20)	0 (0)	7 (20)
Myalgia	4 (11)	0 (0)	4 (11)
Nausea/vomiting	8 (23)	0 (0)	8 (23)
Nervous system disorders	5 (14)	0 (0)	5 (14)
Pain	9 (26)	1 (3)	10 (29)
Pruritis	10 (29)	0 (0)	10 (29)
Rash	6 (17)	1 (3)	7 (20)
Skin disorders	5 (14)	0 (0)	5 (14)

^aShown are TRAEs of any grade that occurred in more than 10% of patients.

signature related to dMMR (that is, signatures 6, 15 and 20; Fig. 4a). Of the seven endometrial/ovarian cancers with a dominant aging-related mutational signature, six had a secondary dMMR signature (Fig. 4a). Notably, the case with the highest TMB in this cohort was MSS; had a dominant aging-related, a secondary dMMR-related and a polymerase epsilon (*POLE*)-related mutational signature; and harbored a pathogenic *POLE* exonuclease domain hotspot mutation (p.F367S

(ref. 29)), in addition to a pathogenic *MSH6* somatic mutation. Comparison between endometrial/ovarian cancers from patients who had clinical benefit (PFS \geq 24 weeks; $n = 19$) versus those who did not (PFS < 24 weeks; $n = 14$) revealed no statistically significant differences in the TMB (18.1 versus 14.4, $P = 0.24$) (Fig. 4b), MSI status (79% versus 79% MSI-H, $P = 1$) and dominant dMMR mutational signature (84% versus 71%, $P = 0.374$). When focusing only on patients with dMMR and available mechanism of dMMR (genetic versus epigenetic; $n = 32$), type of dMMR was not associated with clinical benefit ($P = 0.43$) (Fig. 4c and Extended Data Table 2).

Alterations in PI3K and beta-catenin signaling pathway-related genes, as well as mutations in *JAK1* and *JAK2*, were previously reported to be associated with resistance to immunotherapy in melanoma³⁰. We performed a post hoc analysis focusing on these specific alterations in our cohort, but we observed no strong association between the mutations in *PIK3CA*, *PTEN*, *JAK* or *CTNNA1* and TMB (Extended Data Fig. 3) or with clinical benefit (Extended Data Fig. 4). Furthermore, none of these mutations was significantly associated with immune recognition, as defined by the percentage of CD8⁺PD-1⁺TOX⁺ T cells and interaction between CD8⁺PD-1⁺ T cells and PD-L1⁺ cells, although these analyses were limited by small group sizes (Extended Data Fig. 5). Finally, we observed no strong correlation between the TMB and the immune markers in patients with or without clinical benefit, although these analyses were limited by small numbers (Extended Data Fig. 5). We did observe, however, that mutations affecting the Hedgehog signaling pathway, including *MEGF8* (32% in patients with PFS \geq 24 weeks versus 0% in patients with PFS < 24 weeks, $P = 0.027$) and SET domain-containing 1B (*SETD1B*), a gene encoding histone lysine methyltransferase (58% in patients with PFS \geq 24 weeks versus 14% in patients with PFS < 24 weeks, $P = 0.015$), were statistically significantly different between the tumors from patients who had clinical benefit versus those who did not (Fig. 4d,e). Mutations in *SETD1B* were also strongly associated with increased tumor infiltration with CD8⁺PD-1⁺TOX⁺ T cells (Extended Data Fig. 5), highlighting a potential link between this genetic alteration and immune recognition.

Discussion

In this investigator-initiated phase 2 study, the use of nivolumab for dMMR/MSI-H endometrial or ovarian cancer met the pre-specified endpoint for clinical efficacy, with an ORR of 57% in the evaluable population and 64.7% of patients remaining progression free at 24 weeks. Response to nivolumab was observed in patients regardless of mechanism of dMMR or histologic subtype. Patients benefitted from substantial disease control, with median DOR and OS not yet reached with nearly 3 years of median follow-up. No new safety signals were noted, although rare immune-mediated toxicities, including myocarditis and type 1 diabetes, were seen.

Anti-PD-1/PD-L1 monotherapy has demonstrated robust clinical activity in patients with dMMR/MSI-H tumors^{6,31–33}, both as a tissue-agnostic indication as well as specifically in endometrial cancer.


Unfortunately, up to 60% of patients fail to respond or have progression of disease within 6 months. There remains a need to identify additional biomarkers for response and resistance, even in a favorable patient population, especially given the available data to support adding pembrolizumab or dostarlimab to platinum-based chemotherapy for patients with advanced or recurrent disease^{12,13}.

TMB was used in several studies as a biomarker for response to immunotherapy^{34,35}, and pembrolizumab now has an FDA-approved indication for advanced solid tumors with a TMB of ≥ 10 mutations per megabase (mut/Mb) as measured by the FoundationOne CDx assay. This cutoff was based on studies in lung cancer and has not been rigorously investigated in gynecologic malignancies. TMB has been conceived as a surrogate for tumor neoantigens; however, the quantity of mutations might not be directly related to the quality of mutation necessary to generate a robust T cell response. Moreover, available TMB assays have not been harmonized, leading to inconsistent scoring³⁶. Recent data suggest that small insertions and deletions generate a much stronger immune response compared to single-nucleotide variants (SNVs)³⁷. In our cohort, no significant difference was observed in TMB between responders and non-responders, suggesting that, among patients with dMMR/MSI tumors, TMB has no additional benefit in predicting likely response.

PD-L1 expression, in immune cells, tumor cells or both, has been used as a biomarker for response to PD-1/PD-L1 blockade in several solid tumor types, including lung, cervix and bladder cancers^{38,39}. The value of PD-L1 as a predictive biomarker in dMMR cancers is unclear, and, in our dataset, PD-L1 expression was not predictive of objective response (Fig. 3d). This finding is consistent with previously published studies on PD-L1⁺ endometrial cancer regardless of dMMR/MSI status. In these studies, the ORR to single-agent PD-L1 blockade was modest, with ORRs ranging from 13% to 23% (refs. 40–42). Similarly, data from multiple cancer types have highlighted the prognostic and occasionally predictive value of tumor-infiltrating lymphocytes (TILs). In our dataset, the presence of CD8⁺ T cells was associated with response (Fig. 3), although association was not strong. Emerging data indicate that T cell functional states, rather than T cell numbers, serve as better biomarkers of tumor immunogenicity and potentially response to immune checkpoint blockade^{18,43,44}. Chronic antigen exposure within the context of the TME leads to progressive differentiation of T cells through the stages of activation, early dysfunction and terminal dysfunction, characterized by progressive upregulation of transcriptional programs and surface receptors, such as PD-1, that dampen T cell function⁴⁵. The transcription factor TOX has been identified as the master regulator driving the molecular and epigenetic programs of terminal T cell dysfunction/exhaustion. Several studies have demonstrated that expression of exhaustion markers by T cells is strongly predictive of tumor antigen reactivity. Interestingly, in our dataset, increased proportion of dysfunctional T cells and terminally dysfunctional T cells, defined as CD8⁺PD-1⁺ and CD8⁺PD-1⁺TOX⁺, respectively, was significantly correlated with response²⁰.

Fig. 3 | TME predictors of clinical benefit. Multiplex immunofluorescence imaging using the Vectra system was performed on archival tissue. Analyses were performed on the tumor compartment after excluding stroma. **a**, Representative tumor images from the clinical benefit (CB) and no benefit (NB) patients. Markers assessed in the panel are shown. **b**, Association of CD8⁺ T cells, FoxP3⁺ Treg cells and CD8⁺/FoxP3⁺ ratios with CB. **c**, Association of dysfunctional T cells (CD8⁺PD-1⁺) and terminally dysfunctional T cells (CD8⁺PD-1⁺TOX⁺) with CB. Relative percentages of the indicated populations out of total cells (left two panels) and out of CD8⁺ T cells (right two panels) are shown. **d**, Association of PD-L1 positivity in tumor cells (Pax8⁺) or tumor and immune cells (combined) with CB. **e**, Schematic of CD8⁺ T cell interactions with PD-L1⁺ cells in the TME. **f**, Representative interaction maps of CD8⁺PD-1⁺ T cells with PD-L1⁺ cells in the TME. Spatial plots accounting for all PD-L1⁺ T cells in the TME are shown on the right. **g**, Interaction CD8⁺ T cells with PD-L1⁺ tumor cells (top) and all PD-L1⁺

cells (bottom). **h**, Interaction of CD8⁺ T cells and dysfunctional CD8⁺ T cells with FoxP3⁺ cells in the TME. **i**, Correlation plot of the TME parameters using hierarchical clustering. **j**, Overall association of TME parameters with CB. **k**, Association of percentage of CD8⁺PD-1⁺TOX⁺ T cells and proximity of CD8⁺PD-1⁺ T cells to PD-L1⁺ cells with CB using bottom tertiles as cutoffs. **l**, ROC curve using percentage of CD8⁺PD-1⁺TOX⁺ T cells and proximity of CD8⁺PD-1⁺ T cells to PD-L1⁺ cells as variables. Figure 3b–d,g: $n = 25$; Fig. 3h: $n = 24$. Measure of center represents the median, with error bars representing 95% CI. Two-sided P value by Mann–Whitney test without multiple comparison adjustment is shown. Figure 3i: Pearson correlation without multiple comparison adjustment is indicated by circle size and color. $P < 0.05$, $***P < 0.01$, $****P < 0.001$ and $*****P < 0.0001$, all two-sided. Figure 3k: $n = 25$, chi-square statistical comparisons are shown, two-sided P value. NPV, negative predictive value; PPV, positive predictive value. Image in panel (e) was created with BioRender.






Fig. 4 | Somatic mutations in ovarian and endometrial cancers according to clinical benefit. a, TMB, MSIsensor score, mutational signatures and recurrent non-synonymous somatic mutations identified by whole-exome sequencing in endometrial cancers with clinical benefit (PFS ≥ 24 weeks) and without clinical benefit (PFS < 24 weeks). Cases are represented by columns and genes by rows. Only pathogenic mutations are shown. MSI status, dominant mutational signature, histologic types and mutation types are color-coded according to the legend. Percentages in bold indicate statistically significantly different. * $P < 0.05$, two-sided Fisher's exact test. First, dominant mutational signature;

Second, secondary mutational signature. **b**, Association of CB (defined by PFS24) with TMB. **c**, Association of type of dMMR (genetic versus epigenetic) with CB ($n = 32$; one patient had no information available). **d, e**, Association of mutations in *MEGF8* and *SETD1B* with CB ($n = 33$). Figure 4b: measure of center represents the median, with error bars representing 95% CI. Two-sided P value by Mann-Whitney test is shown. Figure 4c-e: chi-square statistical comparisons are shown, two-sided P value. No multiple comparison adjustment was used for any of the indicated analyses. CB, clinical benefit; NB, no benefit.

As an additional measure of T cell functional states, we examined interaction of CD8⁺ T cells with PD-L1⁺ cells in the TME without distinguishing whether PD-L1 was expressed by cancer cells or cancer-associated myeloid cells. Although PD-L1 expression alone was not predictive of response, the proximity of PD-L1⁺ cells to CD8⁺ TILs was predictive. These findings resonate with recently reported findings in ovarian cancer, in which co-localization of CD8⁺PD-1⁺ T cells with PD-L1-expressing myeloid cells was found to be important for T cell licensing⁴⁶. Findings by Färkkilä et al.⁴⁷ demonstrated that spatial proximity between PD-1⁺ TILs with PD-L1⁺ myeloid cells was associated with improved response to niraparib and pembrolizumab in patients with ovarian cancer.

In an exploratory genomic analysis, we found that alterations in *MEGF8* and *SETD1B* were enriched in patients who derived benefit from nivolumab. *MEGF8* acts as a negative regulator of the Hedgehog signaling pathway⁴⁸. Recently, Hedgehog signaling was shown to modulate the TME by inducing immunosuppressive mechanisms, such as upregulating PD-L1 expression and recruiting immunosuppressive cell populations, including myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)⁴⁹. *SETD1B* is an important component of the histone methyltransferase complex that generates trimethylated histone H3 at Lys4 and has been implicated in multiple biological processes⁵⁰. Interestingly, a related histone methyltransferase SETDB1 was recently demonstrated to play a role in anti-tumor immunity by regulating expression of endogenous retroelements⁵¹. In other tumor models, mutations in the SWI/SNF chromatin remodeling complex, including *PBRM1* and *ARID2*, have been found to sensitize tumor cells to T-cell-mediated killing^{52,53}. In this cohort, we did not identify any significant difference in the rates of *PBRM1* and *ARID2* mutations between patients who did and did not derive clinical benefit. The enrichment

of *SETD1B* mutations in patients who derived clinical benefit, however, suggests that chromatin remodeling may play a larger role in mediating sensitivity to PD-1 blockade beyond the SWI/SNF complex and should be explored further in larger cohorts of patients with dMMR/MSI tumors.

In dMMR/MSI colorectal cancer and melanoma, genomic alterations in antigen-presenting machinery, including loss of beta-2-microglobulin and human leukocyte antigen (HLA) genes, are associated with resistance to checkpoint blockade⁵⁴⁻⁵⁶. In this cohort, we did not note enrichment of any genomic alterations previously implicated in immunotherapy resistance, including *JAK*^{56,57}, *CTNNB1* and *PTEN*⁵⁸. Some previous studies also suggested that patients with Lynch syndrome may have a superior response to pembrolizumab⁵⁹, and a study by Chow et al.¹⁵ demonstrated that genetic, rather than epigenetic, mechanism of dMMR was associated with stronger response to pembrolizumab in patients with dMMR endometrial cancer. Contrary to these findings, in our cohort, no significant difference was observed in the ORR among patients with germline or somatic dMMR alterations and those with *MLH1* hypermethylation.

Our study had several limitations, including a small sample size and access to limited archival tissue, which limited our ability to perform additional correlative studies. In addition, our population may not be reflective of the broader population of patients with dMMR/MSI-H tumors. Most patients in our cohort had high-grade disease (endometrioid or undifferentiated/dedifferentiated), which differs from the published literature, where only 29% of patients with dMMR endometrial cancer had high-grade disease⁶⁰. Lastly, given the small number of patients with Lynch syndrome ($n = 5$), we cannot make any definitive conclusions about this population and how responses may differ from patients with somatic dMMR disease.

In summary, nivolumab achieved a high ORR and durable PFS with acceptable toxicity in patients with dMMR/MSI-H recurrent endometrial or ovarian cancer. In this dMMR-selected patient population, previously described immunotherapy response biomarkers, such as TMB or PD-L1 expression, were not associated with objective response or PFS. Instead, we identified two potential biomarkers associated with PFS in our cohort, including presence of dysfunctional T cells and spatial proximity between T cells and PD-L1-expressing cells in the TME. These parameters could be adaptable for future testing using clinically available immunohistochemistry assays, in which evaluation of 3–4 markers per slide (CD8, PD-1, TOX and PD-L1) would be sufficient. Overall, our findings highlight markers of pre-existing T cell response, as defined by T cell functionality, that may present a strategy for patient selection for anti-PD-1 therapy in dMMR gynecologic cancers and generate rationale for validation of these markers in larger cohorts of patients with dMMR disease.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-024-02942-7>.

References

- Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. *CA Cancer J. Clin.* **73**, 17–48 (2023).
- Muggia, F. M., Blessing, J. A., Sorosky, J. & Reid, G. C. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. *J. Clin. Oncol.* **20**, 2360–2364 (2002).
- Garcia, A. A., Blessing, J. A., Nolte, S. & Mannel, R. S. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. *Gynecol. Oncol.* **111**, 22–26 (2008).
- Miller, D. S., Blessing, J. A., Lentz, S. S. & Waggoner, S. E. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol. Oncol.* **87**, 247–251 (2002).
- Levine, D. A. et al. Integrated genomic characterization of endometrial carcinoma. *Nature* **497**, 67–73 (2013).
- Le, D. T. et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* **357**, 409–413 (2017).
- Xiao, X., Melton, D. W. & Gourley, C. Mismatch repair deficiency in ovarian cancer—molecular characteristics and clinical implications. *Gynecol. Oncol.* **132**, 506–512 (2014).
- Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N. Engl. J. Med.* **372**, 2509–2520 (2015).
- Ott, P. A. et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. *J. Clin. Oncol.* **35**, 2535–2541 (2017).
- Marcus, L., Lemery, S. J., Keegan, P. & Pazdur, R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. *Clin. Cancer Res.* **25**, 3753–3758 (2019).
- US Food and Drug Administration. Highlights of prescribing information: JEMPERLI. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf (2021).
- Mirza, M. R. et al. Dostarlimab for primary advanced or recurrent endometrial cancer. *N. Engl. J. Med.* **388**, 2145–2158 (2023).
- Eskander, R. N. et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. *N. Engl. J. Med.* **388**, 2159–2170 (2023).
- Manning-Geist, B. L. et al. Microsatellite instability–high endometrial cancers with *MLH1* promoter hypermethylation have distinct molecular and clinical profiles. *Clin. Cancer Res.* **28**, 4302–4311 (2022).
- Chow, R. D. et al. Distinct mechanisms of mismatch-repair deficiency delineate two modes of response to anti-PD-1 immunotherapy in endometrial carcinoma. *Cancer Discov.* **13**, 312–331 (2023).
- Gulhan, D. C. et al. Genomic determinants of de novo resistance to immune checkpoint blockade in mismatch repair-deficient endometrial cancer. *JCO Precis. Oncol.* **4**, 492–497 (2020).
- Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. *Mol. Cancer Ther.* **14**, 847–856 (2015).
- Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* **515**, 568–571 (2014).
- Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. *Nature* **545**, 60–65 (2017).
- Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. *Nature* **571**, 270–274 (2019).
- Middha, S. et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. *JCO Precis. Oncol.* **2017**, PO.17.00084 (2017).
- Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat. Med.* **23**, 703–713 (2017).
- Tan, W. C. C. et al. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. *Cancer Commun. (Lond.)* **40**, 135–153 (2020).
- Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. *Cell* **176**, 775–789 (2019).
- Verma, V. et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1^{hi}CD38^{hi} cells and anti-PD-1 resistance. *Nat. Immunol.* **20**, 1231–1243 (2019).
- Philip, M. & Schietinger, A. Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections. *Curr. Opin. Immunol.* **58**, 98–103 (2019).
- Zhou, J. et al. Clinical significance of CD38 and CD101 expression in PD-1^{hi}CD8⁺ T cells in patients with epithelial ovarian cancer. *Oncol. Lett.* **20**, 724–732 (2020).
- Centofanti, E. et al. The spread of interferon- γ in melanomas is highly spatially confined, driving nongenetic variability in tumor cells. *Proc. Natl Acad. Sci. USA* **120**, e2304190120 (2023).
- León-Castillo, A. et al. Interpretation of somatic *POLE* mutations in endometrial carcinoma. *J. Pathol.* **250**, 323–335 (2020).
- Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. *Nat. Rev. Immunol.* **20**, 25–39 (2020).
- Oaknin, A. et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. *JAMA Oncol.* **6**, 1766–1772 (2020).
- Le, D. T. et al. PD-1 blockade in tumors with mismatch repair deficiency. *J. Clin. Oncol.* **33**, https://doi.org/10.1200/jco.2015.33.18_suppl.lba100 (2015).
- Konstantinopoulos, P. A. et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. *J. Clin. Oncol.* **37**, 2786–2794 (2019).
- Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncol.* **21**, 1353–1365 (2020).


35. Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. *N. Engl. J. Med.* **377**, 2500–2501 (2017).
36. Spouge, J. L. et al. Strong conformational propensities enhance T cell antigenicity. *J. Immunol.* **138**, 204–212 (1987).
37. Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. *Lancet Oncol.* **18**, 1009–1021 (2017).
38. Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* **387**, 1540–1550 (2015).
39. Chung, H. C. et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. *J. Clin. Oncol.* **37**, 1470–1478 (2019).
40. Ott, P. A. et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. *J. Clin. Oncol.* **35**, 2535–2541 (2017).
41. Tamura, K. et al. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. *Cancer Sci.* **110**, 2894–2904 (2019).
42. Liu, J. F. et al. Safety, clinical activity and biomarker assessments of atezolizumab from a phase I study in advanced/recurrent ovarian and uterine cancers. *Gynecol. Oncol.* **154**, 314–322 (2019).
43. Kim, C. G. et al. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. *J. Immunother. Cancer* **9**, e002780 (2021).
44. Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. *Nat. Med.* **25**, 454–461 (2019).
45. Wherry, E. J. et al. Molecular signature of CD8⁺ T cell exhaustion during chronic viral infection. *Immunity* **27**, 670–684 (2007).
46. Cascio, S. et al. Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition. *Sci. Adv.* **7**, eabi5790 (2021).
47. Färkkilä, A. et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. *Nat. Commun.* **11**, 1459 (2020).
48. Zhang, Q. & Jiang, J. Regulation of Hedgehog signal transduction by ubiquitination and deubiquitination. *Int. J. Mol. Sci.* **22**, 13338 (2021).
49. Grund-Gröschke, S., Stockmaier, G. & Aberger, F. Hedgehog/GLI signaling in tumor immunity—new therapeutic opportunities and clinical implications. *Cell Commun. Signal.* **17**, 172 (2019).
50. Lee, J. H., Tate, C. M., You, J. S. & Skalnik, D. G. Identification and characterization of the human Set1B histone H3-Lys⁴ methyltransferase complex. *J. Biol. Chem.* **282**, 13419–13428 (2007).
51. Zhang, S. M. et al. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. *Nature* **598**, 682–687 (2021).
52. Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. *Science* **359**, 770–775 (2018).
53. Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. *Science* **359**, 801–806 (2018).
54. Grasso, C. S. et al. Genetic mechanisms of immune evasion in colorectal cancer. *Cancer Discov.* **8**, 730–749 (2018).
55. Snahnicanova, Z. et al. Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer. *Clin. Exp. Med.* **20**, 87–95 (2020).
56. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. *N. Engl. J. Med.* **375**, 819–829 (2016).
57. Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. *Cancer Discov.* **7**, 188–201 (2017).
58. Trujillo, J. A. et al. Secondary resistance to immunotherapy associated with β -catenin pathway activation or PTEN loss in metastatic melanoma. *J. Immunother. Cancer* **7**, 295 (2019).
59. Bellone, S. et al. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. *Cancer* **128**, 1206–1218 (2022).
60. Gordhandas, S. et al. Clinicopathologic features of endometrial cancer with mismatch repair deficiency. *Ecancermedicalscience* **14**, 1061–1061 (2020).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

Claire F. Friedman ^{1,2,3} , **Beryl L. Manning-Geist**⁴, **Qin Zhou**⁵, **Tara Soumerai**¹, **Aliya Holland**², **Arnaud Da Cruz Paula** ⁴, **Hunter Green** ⁶, **Melih Arda Ozsoy**¹, **Alexia Iasonos**⁵, **Travis Hollmann**^{3,6}, **Mario M. Leitao Jr.**^{4,7}, **Jennifer J. Mueller**^{4,7}, **Vicky Makker**^{1,2}, **William P. Tew**^{1,2}, **Roisin E. O'Ceirbhail** ^{1,2}, **Ying L. Liu**^{1,2}, **Maria M. Rubinstein**^{1,2}, **Tiffany Troso-Sandoval**^{1,2}, **Stuart M. Lichtman**^{1,2}, **Alison Schram** ^{1,2}, **Chrisann Kyi**^{1,2}, **Rachel N. Grisham**^{1,2}, **Pamela Causa Andrieu**⁸, **E. John Wherry** ⁹, **Carol Aghajanian**^{1,2}, **Britta Weigelt** ⁶, **Martee L. Hensley**^{1,2} & **Dmitriy Zamarin** ¹⁰ 

¹Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ²Department of Medicine, Weill Cornell Medical College, New York, NY, USA. ³Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ⁴Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ⁵Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ⁶Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ⁷Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, USA. ⁸Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ⁹Institute of Immunology, University of Pennsylvania, Philadelphia, PA, USA. ¹⁰Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.  e-mail: friedmac@mskcc.org; dmitriy.zamarin@mssm.edu

Methods

Study design and procedures

This was a single-center, investigator-initiated, single-arm, phase 2 study conducted at MSK. This study was approved by the institutional review board at MSK and was registered at ClinicalTrials.gov (NCT03241745). This study was performed in accordance with the International Conference on Harmonization of Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. All patients provided informed consent. Sex and/or gender were not considered in the trial design, but all participants were female because of the disease types enrolled. No compensation was provided for participation. The first patient consented on 27 September 2017, and the final patient consented on 24 May 2021. The trial completed as of 1 July 2022. The MSK Data and Safety Monitoring Committee provided independent monitoring for safety, data integrity and study conduct from the enrollment of the first participant until all patients completed treatment. The most recent version of the protocol is provided in the Supplementary Information.

The study underwent two noteworthy amendments. The first, dated 24 April 2018, clarified that clear cell carcinoma and endometrioid carcinoma were eligible histologies; decreased the hemoglobin eligibility value from 9 g dl⁻¹ to 8 g dl⁻¹; clarified that urinalysis could be collected at physician discretion; and added the collection of cell-free DNA (cfDNA) at specified timepoints. The second, dated 30 October 2018, changed the nivolumab dosing from 240 mg intravenously every 2 weeks to 480 mg every 4 weeks as per the Investigational Brochure Version 16.0; removed day 15 visits after cycle 1; and added primary peritoneal cancers as a possible eligible cancer site.

Treatments and follow-up

Nivolumab was administered as 240 mg intravenously every 2 weeks until progression or unacceptable toxicity; this was amended on 30 October 2018 to reflect an updated dosing schedule of 480 mg every 4 weeks. Anti-tumor activity was assessed through radiologic tumor assessments conducted at baseline of starting therapy and every 12 weeks thereafter. RECIST version 1.1 were used to determine response and progression⁶¹. Toxicity data were collected at each visit and classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Eligibility

Patient inclusion criteria included the following.

1. Histologically confirmed diagnosis of metastatic or recurrent uterine cancer (endometrial carcinoma, carcinosarcoma, clear cell carcinoma, leiomyosarcoma, undifferentiated sarcoma and high-grade endometrial stromal sarcoma) by MSK. Carcinosarcomas and endometrioid and clear cell carcinomas that appeared to have arisen in the ovary/fallopian tube or peritoneum were also eligible. Recurrences could not be amenable to curative approaches, such as surgical resection or chemoradiotherapy.
2. Tumor was confirmed to be one of the following: MSI-H or dMMR or hypermutated defined as ≥ 20 somatic mutations in the tumor by MSK-IMPACT.
3. One or more prior lines of cytotoxic treatment for advanced disease (prior hormonal therapy was not considered to count as prior lines of therapy).
4. Measurable disease by RECIST version 1.1.
5. No known central nervous system metastases.
6. Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 1.
7. White blood cell count more than 2,000 per microliter, absolute neutrophil count (ANC) more than 1,500 per microliter, platelet count more than 100,000 per microliter and hemoglobin level more than 8 g dl⁻¹.

8. Serum creatinine less than 1.5× the upper limit of normal (ULN) or creatinine clearance of more than 40 ml min⁻¹ by the Cockcroft–Gault formula.
9. Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) less than 3× ULN.
10. Total bilirubin less than 1.5× ULN, except patients with Gilbert's syndrome who could have total bilirubin less than 3.0 mg dl⁻¹.
11. Able to sign voluntary written informed consent.
12. Female, 18 years of age or older.
13. Available archival tumor tissue or patient was willing to undergo new biopsy.
14. Premenopausal women of childbearing potential must have had a normal urine or serum beta-human chorionic gonadotropin (HCG) before enrollment and must have agreed to use effective contraception during treatment with nivolumab and for at least 5 months after the last dose of nivolumab.

Of note, all patients were assigned as female based on sex at birth given the diseases studied; to our knowledge, none of the patients self-identified as another gender.

Patient exclusion criteria included the following.

1. Disease eligible for potentially curative treatment with standard chemotherapy, surgical resection or chemoradiotherapy.
2. Known or suspected autoimmune disease, except for patients with vitiligo, diabetes mellitus, resolved childhood asthma/atopy, residual hypothyroidism due to an autoimmune immune condition only requiring thyroid hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger.
3. Serious uncontrolled medical disorder or active infection that would impair the ability of the patient to receive protocol therapy or whose control would be jeopardized by protocol therapy.
4. History of bowel obstruction, refractory ascites or bowel perforation due to advanced disease within the past 3 months from start of study treatment.
5. Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways.
6. Patients with a condition that requires systemic treatment with corticosteroids within 7 d of enrollment (systemic corticosteroid therapy is defined as more than 10 mg daily prednisone or its equivalent) or who required other immunosuppressive medications within 14 d of study drug administration. Inhaled or topical steroids and adrenal replacement doses more than 10 mg daily prednisone equivalents were permitted in the absence of active autoimmune disease.
7. Prior history of malignancy or a concurrent malignancy, with the exception of cutaneous basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer or in situ carcinoma of the uterine cervix, prostate or breast, unless a complete remission was achieved at least 3 years before study entry and no additional therapy was required or anticipated to be required during the study period.
8. Breastfeeding women and pregnant women.
9. Prisoners or patients who are involuntarily incarcerated.
10. Patients who are compulsorily detained for treatment of either a psychiatric or a physical illness.
11. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection (if patient had documented hepatitis B or C from within 6 months of enrollment, these tests did not need to be repeated).

12. Known history of testing positive for HIV or known AIDS.
13. Known allergy or adverse drug reaction to nivolumab or a history of allergy to study drug components.

Correlative assessments

Multiplexed immunofluorescence analysis. Primary antibody staining conditions were initially optimized using standard immunohistochemical analysis on the Leica Bond RX automated research stainer with DAB detection (Leica Bond Polymer Refine Detection DS9800). Using 4- μm FFPE tissue sections and serial antibody titrations, the optimal antibody concentration was determined, followed by transition to a seven-color multiplex assay with equivalency. Multiplex immunohistochemical analysis was performed on a Leica Bond RX automated research stainer with DAB detection (Leica Bond Polymer Refine Detection DS9800). The antibody panel included FOXP3 (236A/E7, Biocare), PD-L1 (1:400, E1L3N, Cell Signaling Technology), CD8 (4B11, 1:500, Leica), PAX8 (EPR18715, 1:1,000, Abcam), PD-1 (EPR4877(2), 1:400, Abcam), TOX (E613Q, 1:7,000, Cell Signaling Technology) as well as DAPI. The 4- μm FFPE tissue sections were baked for 3 h at 62 °C with subsequent deparaffinization performed on the Leica Bond RX, followed by six sequential cycles of staining, with each round including a 30-min combined block and primary antibody incubation (PerkinElmer antibody diluent/block ARD1001). For all antibodies, detection was performed using a secondary horseradish peroxidase (HRP)-conjugated polymer (PerkinElmer Opal polymer HRP Ms + Rb ARH1001, 10-min incubation). The HRP-conjugated secondary antibody polymer was detected using fluorescent tyramide signal amplification using Opal dyes 520 (TOX), 540 (PD-1), 570 (CD8), 620 (PD-L1), 650 (FoxP3) and 690 (PAX8) (Perkin Elmer FP1487a, FP1494a, FP1488a, FP1496a, FP1495a and FP1497a). The covalent tyramide reaction was followed by heat-induced stripping of the primary/secondary antibody complex using PerkinElmer AR9 buffer (AR900250ML) at 100 °C for 20 min preceding the next cycle. After six sequential rounds of staining, sections were stained with Hoechst (Invitrogen, 33342) to visualize nuclei and mounted with ProLong Gold antifade reagent mounting medium (Invitrogen, P36930). Seven-color multiplex-stained slides were imaged using the Vectra Multispectral Imaging System version 3 (PerkinElmer). Scanning was performed at $\times 20$ ($\times 200$ final magnification). Filter cubes used for multispectral imaging were DAPI, FITC, Cy3, Texas Red and Cy5. A spectral library containing the emitted spectral peaks of the fluorophores in this study was created using Vectra image analysis software (PerkinElmer). Using multispectral images from single-stained slides for each marker, the spectral library was used to separate each multispectral cube into individual components (spectral unmixing), allowing for identification of the seven marker channels of interest using inForm 2.4 image analysis software.

Immunofluorescence analyses. Images were exported to Indica Labs HALO image analysis platform, and cell segmentation and signal thresholding were performed separately on each case using a supervised algorithm. The entire scanned slide area was analyzed with a median number of 66,935 DAPI⁺ cells (range, 641–164,584). Individual cell populations were quantified in both tumor and stromal compartments, with quantifications in tumor compartment reported. For individual cell populations, percentages out of total nucleated cells are reported unless otherwise specified. To quantify the cell interactions, average distances between the specified cells of interest were initially computed. The distance of 50 μm was arbitrarily chosen as a cutoff for further proximity analyses, as it represents a neighborhood of 2–3 cells and is consistent with a reported distance of T-cell-produced IFN- γ action on the neighboring cells, which is estimated to be 30–40 μm (ref. 28). This is similar to cutoffs used in studies of other cancer types⁶². To quantify the cell interactions, the number of the specified cells located within 50 μm of the interacting cells was divided by the total number of the specified cells quantified in the analyzed slide area.

For example, to calculate the percentage of PD-L1⁺ cells that are located within 50 μm of CD8⁺PD-1⁺ cells, the number of PD-L1⁺ cells located within 50 μm of CD8⁺PD-1⁺ cells was divided by the total number of PD-L1⁺ cells in the analyzed area. For the cases in which more than one archival tumor was analyzed, data presented represent an average of measurements between the individual samples.

Whole-exome sequencing. Whole-exome recapture of tumor and patient-matched germline DNA libraries that previously underwent clinical FDA-authorized MSK-IMPACT targeted NGS was performed, as previously described^{22,63}. Whole-exome sequencing data were analyzed as previously described⁶⁴. Mutations affecting hotspot codons were annotated according to Chang et al.⁶⁵. A somatic mutation was defined as pathogenic if it affected a mutational hotspot or was deleterious/loss-of-function in the case of tumor suppressor genes, as previously described⁶⁶. deconstructSigs⁶⁷ at default parameters was used to infer mutational signatures (COSMIC, version 3.1) using all SNVs of a given endometrial/ovarian cancer, as previously described⁶⁸. MSIsensor was employed according to Niu et al.⁶⁹, and samples with MSIsensor score ≥ 3.5 were considered MSI-H. TMB was calculated by dividing the number of non-synonymous mutations by the total size of the capture panel in megabases. Germline mutational status as indicated in Extended Data Table 2 was established via sequencing of matched normal blood using MSK-IMPACT assay after patient consent to germline analysis.

Statistical methods. The co-primary objectives were to define (1) PFS24 and (2) the proportion of patients who achieved objective tumor response (ORR) by RECIST version 1.1 (ref. 61). Secondary objectives included PFS, OS, safety and toxicity, DOR and DCR. Exploratory objectives were to (1) correlate the somatic mutational burden with ORR and PFS24; (2) correlate the somatic mutational burden with MSIsensor score; (3) correlate MSIsensor score with MMR immunohistochemistry status; and (4) correlate the pre-treatment immune phenotype with ORR and PFS24.

The sample size calculation for this study was based on a non-promising ORR of 5% and a promising ORR of 25%. To that end, we used a Simon two-stage minimax design. In the first stage, we enrolled 23 eligible patients, and at least two patients were required to achieve a response to proceed to stage II. In stage II, an additional 17 patients were enrolled. Among the total 40 patients, if six or more patients achieved a response, this treatment regimen would be declared promising. This decision rule had a type I error rate of 0.025 and a type II error rate of 0.05.

PFS24 was the co-primary endpoint. The sample size calculation for this study was based on a non-promising PFS24 of 25% and a promising PFS24 of 50%. Using a Simon two-stage minimax design, in the first stage, we enrolled 23 eligible patients; at least five patients of the initial 17 were required to be progression free at 24 weeks to proceed to stage II. In stage II, an additional 17 patients were enrolled. Among the total 40 patients, if 16 or more patients were progression free at 24 weeks, this treatment regimen would be declared promising. This decision rule had a type I error rate of 0.025 and a type II error rate of 0.09. The study continued to stage II if either ORR or PFS24 was promising. If there was one or fewer objective responses in stage I out of 23 patients, then accrual would be held to determine if at least five of 17 patients remained progression free at 24 weeks.

Patients were evaluable for efficacy if they had received at least one dose of therapy and had at least one post-baseline efficacy assessment. Patients who were evaluable for response and were lost to follow-up or died before the 24-week PFS assessment were considered events.

PFS was calculated from start of treatment to progression/recurrence or death or last follow-up, whichever occurred first. OS was calculated from start of treatment to death or last follow-up, whichever occurred first. DOR was calculated from time of response (for complete response or partial response) to progression, death or last follow-up.

OS, PFS and DOR rates were estimated using the Kaplan–Meier method. Adverse events were tabulated.

The study opened to accrual on 3 August 2017. As per the Simon two-stage minimax design, the study met the criteria to continue to the second stage and was closed to accrual on 2 March 2022, because the primary endpoint of at least six objective responses was met with a final accrual of 35 patients.

Correlation of response with translational parameters was performed by dichotomizing patients based on PFS24, and distribution of the continuous biomarkers (for example, percentages of CD8⁺PD1⁺ cells) between the two groups was compared using the Mann–Whitney test. TMBs were compared using the Mann–Whitney test, and comparisons of frequency of mutations were performed using two-tailed Fisher's exact tests. For exploratory translational analyses, no adjustments for multiple comparisons were performed. Figures were generated using GraphPad Prism 9.5 and R 4.2.3 software.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Datasets generated and analyzed in this study are available for general research use. The MSK-IMPACT dataset is available for browsing via cBioPortal (https://www.cbioportal.org/study/summary?id=ucec_msk_2024). MpIF images will be available from Synapse (<https://www.synapse.org/#!Synapse:syn53699039/files/>). Controlled-tier datasets requiring access approval are available by requesting authorization to the Data Access Committee via dbGAP (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001783.v6.p1). External requests for the data (friedmac@mskcc.org) will be evaluated within a period of 2–3 weeks to ensure that they are in compliance with the data-sharing policies outlined in the informed consent.

References

- Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur. J. Cancer* **45**, 228–247 (2009).
- Tsakiroglou, A. M. et al. Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma. *Br. J. Cancer* **122**, 539–544 (2020).
- Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. *J. Mol. Diagn.* **17**, 251–264 (2015).
- Safdar, N. S. et al. Genomic determinants of early recurrences in low-stage, low-grade endometrioid endometrial carcinoma. *J. Natl Cancer Inst.* **114**, 1545–1548 (2022).
- Chang, M. T. et al. Accelerating discovery of functional mutant alleles in cancer. *Cancer Discov.* **8**, 174–183 (2018).
- Moukarzel, L. A. et al. The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. *Mol. Oncol.* **15**, 1024–1039 (2021).
- Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. *Genome Biol.* **17**, 31 (2016).
- Ashley, C. W. et al. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. *Gynecol. Oncol.* **152**, 11–19 (2019).
- Niu, B. et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. *Bioinformatics* **30**, 1015–1016 (2014).

Acknowledgements

This study was supported, in part, by a National Cancer Institute/National Institutes of Health Cancer Center Support Grant (P30 CA008748), by Stand Up to Cancer (C.F.), by the GOG Foundation (D.Z.), by Cycle for Survival (B.W.) and by the Breast Cancer Research Foundation (B.W.). This clinical trial had funding support provided by Bristol Myers Squibb and Stand Up to Cancer. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. C.F. and D.Z. are members of the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center.

Author contributions

C.F.F.: Conceptualization, Investigation, Data curation, Writing—original draft, Writing—review and editing, Supervision, Project administration and Funding acquisition. B.L.M.-G.: Investigation, Data curation, Writing—original draft and Writing—review and editing. Q.Z.: Methodology, Statistical analysis and Writing—review and editing. T.S.: Conceptualization and Writing—review and editing. A.H.: Investigation and Writing—review and editing. A.D.C.P.: Investigation, Data curation, Formal analysis, Writing—review and editing and Visualization. H.G.: Investigation, Data curation, Formal analysis and Writing—review and editing. M.O.: Investigation, Data curation, Formal analysis and Writing—review and editing. A.I.: Methodology, Statistical analysis and Writing—review and editing. T.H.: Resources and Investigation. M.M.L.: Investigation and Writing—review and editing. J.J.M.: Investigation and Writing—review and editing. V.M.: Investigation and Writing—review and editing. W.P.T.: Investigation and Writing—review and editing. R.E.O.: Investigation and Writing—review and editing. Y.L.L.: Investigation and Writing—review and editing. M.M.R.: Investigation and Writing—review and editing. T.T.-S.: Investigation and Writing—review and editing. S.M.L.: Investigation and Writing—review and editing. A.S.: Investigation and Writing—review and editing. C.K.: Investigation and Writing—review and editing. R.N.G.: Investigation and Writing—review and editing. P.C.A.: Investigation and Writing—review and editing. E.J.W.: Investigation and Writing—review and editing. C.A.: Investigation and Writing—review and editing. B.W.: Conceptualization, Methodology, Formal analysis, Investigation, Resources and Writing—review and editing. M.L.H.: Conceptualization, Investigation, Visualization and Writing—review and editing. D.Z.: Conceptualization, Investigation, Data curation, Formal analysis, Statistical analysis, Writing—original draft, Writing—review and editing, Visualization, Supervision, Project administration and Funding acquisition.

Competing interests

C.F.F. reports ongoing institutional research support from Merck, Bristol Myers Squibb, AstraZeneca, Mersana, Hotspot Therapeutics, Immunocore, Marengo and Volastra; consulting fees from Bristol Myers Squibb, Seagen, Aadi Biosciences and Eli Lilly; honoraria for lectures from OncoLive; meeting/travel support by Puma Biotechnology; and participation on data safety monitoring board or advisory board of Merck, Genentech and Marengo (all uncompensated). A.I. reports consulting fees from Mylan. T.H. is currently employed by Bristol Myers Squibb and has received research funding from Calico Labs, Bristol Myers Squibb and PICI. M.M.L. reports research funding paid to the institution from KCI/Acelity; ad hoc speaker for Intuitive Surgical; and advisory board participation for Johnson & Johnson/Ethicon and Takeda. V.M. reports meeting/travel support from Eisai and Merck; participation on data safety monitoring or advisory boards of Duality, Merck, Karyopharm, Exelixis, Eisai, Karyopharm, Bristol Myers Squibb, Clovis, Faeth Immunocore, Morphosys, AstraZeneca, Novartis, GlaxoSmithKline and Bayer (all uncompensated); and study support to the institution from Merck, Eisai, AstraZeneca, Faeth

Immunocore, Karyopharm, Zymeworks, Duality, Clovis, Bayer and Takeda. R.E.O. reports personal fees from Tesaro/GlaxoSmithKline, Regeneron, R-PHARM, Seattle Genetics, Fresenius Kabi, the Gynecologic Oncology Foundation, Bayer, Curio, Miltenyi, 2seventybio and Immunogen and Other from Hitech Health, all outside the submitted work. She is an uncompensated steering committee member for the PRIMA, Moonstone (Tesaro/GlaxoSmithKline) and DUO-O (AstraZeneca) studies and an uncompensated advisor for Carina Biotech. Her institute receives funding for clinical research from Bayer/Celgene/Juno, Tesaro/GlaxoSmithKline, Merck, the Ludwig Cancer Institute, AbbVie/StemCentrx, Regeneron, TCR2 Therapeutics, Atara Biotherapeutics, MarkerTherapeutics, Syndax Pharmaceuticals, Genmab/Seagen Therapeutics, Sellas Therapeutics, Genentech, Kite Pharma, Acrivon, Lyell Immunopharma and the Gynecologic Oncology Foundation. Y.L.L. reports institutional research funding from Repare Therapeutics, AstraZeneca and GlaxoSmithKline; honoraria from Total Health and Sarah Lawrence College; and travel/meeting support by AstraZeneca, all outside the submitted work. M.M.R. reports research funding from Merck, Zentalis and AstraZeneca. A.S. reports advisory board participation with Relay Therapeutics, Mersana and Merus; consulting with Blueprint Bio and Flagship Pioneering; steering committee participation with Merus and Pfizer; research funding paid to the institution from AstraZeneca, ArQule, BeiGene/Springworks, Black Diamond Therapeutics, Elevation Oncology, Kura, Eli Lilly, Merus, Northern Biologics, Pfizer, PMV Pharma, Relay, Repare Therapeutics, Revolution Medicine and Surface Oncology; and food and beverage from PUMA and Repare Therapeutics. C.K. reports grant funding from the Conquer Cancer Foundation; grant funding paid to the institution from Merus, Gritstone and Bristol Myers Squibb; and consulting fees from Scenic Immunology B.V. and OncLive. R.N.G. reports honoraria from GlaxoSmithKline, AstraZeneca, Natera, Springworks, Corcept, MJH and PER. C.A. reports clinical trial funding paid to the institution from AstraZeneca; consulting fees (advisory board) from Eisai/Merck, Roche/Genentech, AbbVie, AstraZeneca/Merck and Repare Therapeutics; advisory board participation (uncompensated) for Blueprint Medicine; and leadership/fiduciary roles for the GOG Foundation Board of Directors (travel cost reimbursement) and the

NRG Oncology Board of Directors (uncompensated). B.W. reports a research grant from REPARE Therapeutics paid to the institution, outside the submitted work. M.L.H. reports advisory board participation at Aadi Bioscience, GlaxoSmithKline, Thrive Bioscience and Eli Lilly; an immediate family member who is employed by Sanofi; and service as a CME faculty speaker for Research to Practice. E.J.W. is a member of the Parker Institute for Cancer Immunotherapy, which supports research in the Wherry laboratory; an advisor for Danger Bio, Marengo, Janssen, NewLimit, Pluto Immunotherapeutics, Related Sciences, Santa Ana Bio, Synthekine and Surface Oncology; and is a founder of and holds stock in Surface Oncology, Danger Bio and Arsenal Biosciences. D.Z. reports institutional research support from AstraZeneca, Merck, Plexikon, Synthekine and Genentech; consulting fees from AstraZeneca, Synthekine, Astellas, Tessa Therapeutics, Memgen, Celldex, Crown Biosciences, Hookipa Biotech, Kalivir, Xencor and GlaxoSmithKline; royalties from Merck; and stock options from Accurius Therapeutics, ImmunOS Therapeutics and Calidi Biotherapeutics, all outside the submitted work. The other authors do not have potential conflicts of interest to declare.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41591-024-02942-7>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41591-024-02942-7>.

Correspondence and requests for materials should be addressed to Claire F. Friedman or Dmitriy Zamarin.


Peer review information *Nature Medicine* thanks Fernanda Herrera and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Anna Maria Ranzoni, in collaboration with the *Nature Medicine* team.

Reprints and permissions information is available at www.nature.com/reprints.


**Extended Data Fig. 1 | Proximity between T cells and the nearest PD-L1+ cells.**

Extended Data Fig. 1 Proximity between T cells and the nearest PD-L1+ cells. Average distances from the CD8+ T cell. (a) or CD8+PD-1+ T cell (b) to the nearest

PD-L1+ cell in um were calculated in each sample. Measure of centre represents the median with error bars representing 95% CI. Two-sided *P* value by Mann-Whitney test without multiple comparison adjustment is shown.




Extended Data Fig. 2 | Full mutation Oncoprint for the entire patient cohort. Extended Data Fig. 2 Full mutation Oncoprint for the entire patient cohort. Patients are separated on the basis of clinical benefit, defined by progression-free survival (PFS) ≥ 24 weeks (n = 19) and PFS < 24 weeks (n = 14).




Extended Data Fig. 3 | Association of individual mutations with tumor mutational burden (TMB). Extended Data Fig. 3 Association of individual mutations with tumor mutational burden (TMB). Presence or absence of the individual mutations known to be associated with immune resistance in other

cancers was plotted against TMB. Measure of centre represents the median with error bars representing 95% CI. Two-sided *P* value by Mann-Whitney test without multiple comparison adjustment is shown.



Extended Data Fig. 4 | Association of individual mutations with clinical benefit. Extended Data Fig. 4 Association of individual mutations with clinical benefit. Presence or absence of the individual mutations known to be associated with immune resistance in other cancers was compared between patients with

clinical benefit vs no benefit. $N = 33$, Chi-square statistical comparisons without multiple comparison adjustment are shown, two-sided P value. CB, clinical benefit; NB, no benefit.



Extended Data Fig. 5 | Association of molecular alterations with immune phenotypes. Extended Data Fig. 5 Association of molecular alterations with immune phenotypes. Presence or absence of the individual mutations known to be associated with immune resistance in other cancers was compared to the immune phenotypes associated with clinical benefit in the current study. **a.** Association between the individual mutations and CD8+PD-1+TOX+ T cells. **b.** Association between the individual mutations and interaction between

CD8+PD-1+ T cells and PD-L1+ cells. **(a,b):** N = 24. Statistical comparisons were performed using Mann-Whitney test. Measure of centre represents the median with error bars representing 95% CI. Two-sided P value by Mann-Whitney test without multiple comparison adjustment is shown. **c.** Association between tumor mutational burden and immune phenotypes. Pearson correlation coefficients with two-sided P values are shown (N = 24).

Extended Data Table 1 | ORRs in patients with dMMR or MSI-H endometrial or ovarian cancer

	Evaluable Cohort (n=34)	Total Cohort (n=35)
Median follow-up (range), months	42.1 (8.9-59.8)	
ORR (97.5% CI)	58.8% (40.7%-100%)	57.1% (39.4%-100%)
Best confirmed response, n (%)		
Complete response	7 (21%)	7 (20%)
Partial response	13 (38%)	13 (37%)
Stable disease	5 (15%)	5 (14%)
Progression of disease, n (%)	9 (26%)	9 (26%)
Not evaluable, n (%)	0 (0%)	1 (3%)
DCR (97.5% CI)	73.5% (55.6%-87.1%)	71.4% (53.7%-85.4%)
Median DOR	Not Reached	

Abbreviations: ORR, objective response rate; CI, confidence interval; DCR, disease control rate; DOR, duration of response.

Extended Data Table 2 | Association of clinical and dMMR characteristics with clinical outcomes

ID	Age	Histology	MMR by IHC	Mechanism of dMMR/ Hypermethylation	Germline vs Sporadic dMMR	TMB (mut/Mb by WES)	TMB-H (MSK-IMPACT)	PFS24 outcome	ORR outcome
1	64	Endometrioid, grade 3	pMMR	Hypermutation	Sporadic	11.86	Yes	Yes	Yes
2	77	Endometrioid, grade 1	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	NA	No	No	No
3	70	Endometrioid, grade 2	absent MLH1/PMS2	MLH1 germline epimutation	Germline	20.99	Yes	No	Yes
4	77	Endometrioid, grade 2	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	18.73	Yes	No	No
5	51	Clear cell carcinoma, uterine	absent MLH1/PMS2	Somatic	Sporadic	27.78	Yes	Yes	Yes
6	79	Endometrioid, grade 1	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	7.48	Yes	No	No
7	80	Endometrioid, grade 3	absent MLH1 (indeterminant)	pMMR	NA	1.39	No	No	No
8	64	Endometrioid, grade 3	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	24.05	Yes	No	No
9	58	Dedifferentiated	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	24.28	Yes	Yes	Yes
10	68	Endometrioid, grade 2	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	12.14	Yes	Yes	Yes
11	57	Dedifferentiated/undifferentiated	absent MLH1/PMS2/ MSH6	MLH1 Hypermethylation	Sporadic	17	Yes	No	Yes
12	63	Endometrioid, grade 1	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	14.22	Yes	Yes	Yes
14	69	Endometrioid, grade 3	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	14.22	Yes	Yes	Yes
15	87	Clear cell carcinoma, uterine	absent MSH6	Somatic	Sporadic	33.62	Yes	Yes	Yes
16	36	Dedifferentiated/undifferentiated	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	6.97	Yes	No	No
13	65	Endometrioid, grade 1	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	11.65	Yes	No	No
17	68	Endometrioid, grade 2	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	49.1	Yes	Yes	Yes
18	63	Dedifferentiated/undifferentiated	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	25.59	Yes	Yes	Yes
19	57	Endometrioid, grade 3	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	12.78	Yes	No	No
20	51	Endometrioid, grade 3	absent PMS2	Germline PMS2	Germline	168.71	Yes	Yes	Yes
21	64	Endometrioid, grade 1	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	5.84	Yes	Yes	Yes
22	74	Endometrioid, grade 2	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	7.48	Yes	Yes	Yes
23	41	Ovarian endometrioid, grade 3	Not performed	Germline MSH2	Germline	20.32	Yes	Yes	Yes
24	46	Endometrioid, grade 3	absent MSH2/MSH6	Germline MSH2	Germline	29.14	Yes	No	No
25	76	Endometrioid, grade 3	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	13.53	Yes	No	No
26	73	Endometrioid, grade 3	absent MLH1/PMS2	Presumed MLH1 Hypermethylation (testing failed)	Sporadic	26.85	Yes	Yes	Yes
27	45	Ovarian clear cell carcinoma	absent MSH2/MSH6	Germline MSH2	Germline	18.11	Yes	Yes	Yes
28	75	Endometrioid, grade 1	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	13.92	Yes	Yes	Yes
29	50	Endometrioid, grade 3	absent MLH1/PMS2	Presumed MLH1 Hypermethylation (testing not performed)	Sporadic	22.04	Yes	Yes	No
30	68	Endometrioid, grade 3	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	28.06	Yes	No	No
31	62	Endometrioid, grade 2	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	14.22	Yes	Yes	Yes
33	60	Endometrioid, grade 1	pMMR	Hypermutation	Sporadic	7.64	Yes	No	No
35	73	Endometrioid, grade 2	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	15.28	Yes	No	No
36	76	Endometrioid, grade 3	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	11.57	Yes	Yes	Yes
34	63	Endometrioid, grade 1	absent MLH1/PMS2	MLH1 Hypermethylation	Sporadic	NA	Yes	No	No

Abbreviations: MMR, mismatch repair; dMMR, mismatch repair deficient; MSI-H, microsatellite instability high; IHC, immunohistochemistry; pMMR, mismatch repair proficient; TMB, tumor mutational burden; PFS24, progression-free survival at 24 weeks; ORR, objective response rate; mut/Mb, mutations per megabase; WES, whole exome sequencing; TMB-H, high tumor mutational burden; MSK-IMPACT, Memorial Sloan Kettering Cancer Center-Integrated Mutation Profiling of Actionable Cancer Targets.

Extended Data Table 3 | All TRAEs

Toxicity	Grade 1/2, n (%)	Grade 3/4, n (%)	Any Grade, n (%)
Abdominal distension/bloating	2 (6)	1 (3)	3 (9)
Acute kidney injury	0 (0)	1 (3)	1 (3)
Acute optic neuritis	0 (0)	1 (3)	1 (3)
Alanine aminotransferase increased	1 (3)	1 (3)	2 (6)
Alkaline phosphatase increased	3 (9)	0 (0)	3 (9)
Alopecia	2 (6)	0 (0)	2 (6)
Anemia	0 (0)	4 (11)	4 (11)
Anorexia	7 (20)	1 (3)	8 (23)
Arthralgia	9 (26)	1 (3)	10 (29)
Ascites	1 (3)	0 (0)	1 (3)
Aspartate aminotransferase increased	3 (9)	0 (0)	3 (9)
Atrioventricular block complete	0 (0)	1 (3)	1 (3)
Blood bilirubin increased	1 (3)	0 (0)	1 (3)
Chills	2 (6)	0 (0)	2 (6)
Confusion	1 (3)	1 (3)	2 (6)
Constipation	7 (20)	0 (0)	7 (20)
Cough	4 (11)	0 (0)	4 (11)
Creatinine increased	2 (6)	0 (0)	2 (6)
Depression	4 (11)	0 (0)	4 (11)
Diarrhea	13 (37)	0 (0)	13 (37)
Dyspnea	8 (23)	2 (6)	10 (29)
Ear disorders	3 (9)	0 (0)	3 (9)
Edema	5 (14)	0 (0)	5 (14)
Electrolyte disturbances	3 (9)	4 (11)	7 (20)
Elevated lipase	1 (3)	2 (6)	3 (9)
Eye disorders	5 (14)	0 (0)	5 (14)
Fall	5 (14)	0 (0)	5 (14)
Fatigue	14 (40)	0 (0)	14 (40)
Fever	9 (26)	0 (0)	9 (26)
Gastrointestinal disorders	11 (31)	0 (0)	11 (31)
Hemolysis	0 (0)	1 (3)	1 (3)
Hemorrhage	2 (6)	1 (3)	3 (9)
Hot flashes	2 (6)	0 (0)	2 (6)
Hyperglycemia	3 (9)	2 (6)	5 (14)
Hypertension	5 (14)	1 (3)	6 (17)
Hypotension	2 (6)	0 (0)	2 (6)
Hypothyroidism	3 (9)	0 (0)	3 (9)
Infection	12 (34)	1 (3)	13 (37)
Insomnia	2 (6)	0 (0)	2 (6)
Leg cramps	1 (3)	0 (0)	1 (3)
Lymphocyte count decreased	1 (3)	0 (0)	1 (3)
Malaise	2 (6)	0 (0)	2 (6)
Mucositis	2 (6)	0 (0)	2 (6)
Myalgia	4 (11)	0 (0)	4 (11)
Myasthenia gravis	1 (3)	0 (0)	1 (3)
Myocarditis	0 (0)	1 (3)	1 (3)
Nausea/vomiting	15 (43)	3 (9)	18 (51)
Nervous system disorders	12 (34)	1 (3)	13 (37)
Night sweats	1 (3)	0 (0)	1 (3)
Pain	12 (34)	4 (11)	16 (46)
Pancreatitis	0 (0)	1 (3)	1 (3)
Peripheral sensory neuropathy	4 (11)	0 (0)	4 (11)
Pneumonitis	1 (3)	0 (0)	1 (3)
Pruritis	10 (29)	0 (0)	10 (29)
Rash	7 (20)	1 (3)	8 (23)
Renal and urinary disorders	6 (17)	1 (3)	7 (20)
Reproductive system disorders	8 (23)	0 (0)	8 (23)
Respiratory disorders	8 (23)	0 (0)	8 (23)
Serum amylase increased	1 (3)	0 (0)	1 (3)
Skin disorders	6 (17)	0 (0)	6 (17)
Small intestinal obstruction	0 (0)	1 (3)	1 (3)
Thromboembolic event	0 (0)	3 (9)	3 (9)
Type 1 diabetes	0 (0)	1 (3)	1 (3)
Weakness	3 (9)	0 (0)	3 (9)
Weight gain	2 (6)	0 (0)	2 (6)
Weight loss	2 (6)	0 (0)	2 (6)
Overall Toxicity	15 (43)	20 (57)	35 (100)

Extended Data Table 4 | All TRAEs

Toxicity	Grade 1/2, n (%)	Grade 3/4, n (%)	Any Grade, n (%)
Acute optic neuritis	0 (0)	1 (3)	1 (3)
Alanine aminotransferase increased	0 (0)	1 (3)	1 (3)
Alkaline phosphatase increased	1 (3)	0 (0)	1 (3)
Anemia	0 (0)	1 (3)	1 (3)
Anorexia	3 (9)	0 (0)	3 (9)
Arthralgia	9 (26)	1 (3)	10 (29)
Aspartate aminotransferase increased	3 (9)	0 (0)	3 (9)
Atrioventricular block complete	0 (0)	1 (3)	1 (3)
Chills	1 (3)	0 (0)	1 (3)
Constipation	2 (6)	0 (0)	2 (6)
Cough	1 (3)	0 (0)	1 (3)
Diarrhea	7 (20)	0 (0)	7 (20)
Dyspnea	6 (17)	1 (3)	7 (20)
Edema	1 (3)	0 (0)	1 (3)
Electrolyte disturbances	0 (0)	1 (3)	1 (3)
Elevated lipase	1 (3)	2 (6)	3 (9)
Eye disorders	3 (9)	0 (0)	3 (9)
Fatigue	10 (29)	0 (0)	10 (29)
Fever	1 (3)	0 (0)	1 (3)
Gastrointestinal disorders	7 (20)	0 (0)	7 (20)
Hemolysis	0 (0)	1 (3)	1 (3)
Hot flashes	1 (3)	0 (0)	1 (3)
Hyperglycemia	0 (0)	1 (3)	1 (3)
Hypotension	1 (3)	0 (0)	1 (3)
Hypothyroidism	3 (9)	0 (0)	3 (9)
Infection	2 (6)	0 (0)	2 (6)
Leg cramps	1 (3)	0 (0)	1 (3)
Lymphocyte count decreased	1 (3)	0 (0)	1 (3)
Malaise	2 (6)	0 (0)	2 (6)
Mucositis	2 (6)	0 (0)	2 (6)
Myalgia	4 (11)	0 (0)	4 (11)
Myasthenia gravis	1 (3)	0 (0)	1 (3)
Myocarditis	0 (0)	1 (3)	1 (3)
Nausea/vomiting	8 (23)	0 (0)	8 (23)
Nervous system disorders	5 (14)	0 (0)	5 (14)
Night sweats	1 (3)	0 (0)	1 (3)
Pain	9 (26)	1 (3)	10 (29)
Pancreatitis	0 (0)	1 (3)	1 (3)
Peripheral sensory neuropathy	2 (6)	0 (0)	2 (6)
Pneumonitis	1 (3)	0 (0)	1 (3)
Pruritis	10 (29)	0 (0)	10 (29)
Rash	6 (17)	1 (3)	7 (20)
Respiratory disorders	1 (3)	0 (0)	1 (3)
Serum amylase increased	1 (3)	0 (0)	1 (3)
Skin disorders	5 (14)	0 (0)	5 (14)
Thromboembolic event	0 (0)	1 (3)	1 (3)
Type 1 diabetes	0 (0)	1 (3)	1 (3)
Weakness	2 (6)	0 (0)	2 (6)
Weight gain	2 (6)	0 (0)	2 (6)
Weight loss	1 (3)	0 (0)	1 (3)
Overall Toxicity	22 (63)	10 (29)	32 (91)

Extended Data Table 5 | Summary of AEs

Safety Summary	n (%)	95% CI
Any TEAE	35 (100)	90.0-100.0
Grade \geq 3 TEAE	20 (57)	39.4-73.7
Any grade TRAE	32 (91)	76.9-98.2
Grade \geq 3 TRAE	10 (29)	14.6-46.3

Abbreviations: TEAE, treatment-emergent adverse event; TRAE, treatment-related adverse event; CI, confidence interval.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- | | | |
|-------------------------------------|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A description of all covariates tested |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

MSK IMPACT data will be released on cBioPortal upon publication. mpf images will be available from the Biolmage Archive. Whole exome sequencing data will be deposited in dbGAP.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	All patients enrolled on this study are female (based on the fact we enrolled only patients with advanced or recurrent gynecologic cancers).
Reporting on race, ethnicity, or other socially relevant groupings	Race and ethnicities are documented as reported by the patient. These are reported in Table 1 as part of the demographic results, but no additional analyses were performed based on self-reported race or ethnicity.
Population characteristics	Eligible patients had recurrent endometrial cancer or a carcinosarcoma, endometrioid or clear cell carcinoma that appeared to have originated in the ovary/fallopian tube or peritoneum, and met one of the following criteria: dMMR, as determined by loss of expression assessed by immunohistochemistry of one or more of the MMR proteins (MSH2, MSH6, MLH1, and PMS2); 2) MSI-H, as determined by next-generation sequencing (NGS) using Memorial Sloan Kettering Cancer Center-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT; MSIsensor); or 3) hypermutated tumors, defined as 20 or more non-synonymous somatic mutations on MSK-IMPACT. The median age was 64 years (range, 36-87 years), and 77% of patients were White, 11% were Black, and 6% were Asian. Most patients (83%) had endometrioid endometrial cancer. All patients had a good performance status, with an ECOG of 0 or 1.
Recruitment	Patients were recruited from the Gynecologic Medical Oncology clinics at Memorial Sloan Kettering Cancer Center (MSK). The study was offered to patients who were judged to be potentially eligible by their treating physicians. MSK is a tertiary referral center, and thus the patient population may not be reflective of the general gynecologic cancer population. In order to participate in the clinical trial, patients had to have a good performance status and organ function; thus, they are likely to be healthier than the general cancer population.
Ethics oversight	This study was reviewed and approved by the Institutional Review Board at Memorial Sloan Kettering Cancer Center.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	The co-primary objectives were to define 1) PFS24, and 2) the proportion of patients who achieved objective tumor response (ORR) by RECIST v1.1. The sample size calculation for this study was based on a non-promising ORR of 5% and a promising ORR of 25%. To that end, we used a Simon two-stage minimax design. In the first stage, we enrolled 23 eligible patients, and at least 2 patients were required to achieve a response to proceed to stage II. In stage II, an additional 17 patients were enrolled. Among the total 40 patients, if 6 or more patients achieved a response, this treatment regimen would be declared promising. This decision rule had a type I error rate of 0.025 and a type II error rate of 0.05.
Data exclusions	No data were excluded.
Replication	Due to limited human samples, no replication was performed.
Randomization	This was a single arm, phase 2 study. There was only one study group, all of whom received single agent nivolumab. Thus, randomization is not applicable to this study.
Blinding	Blinding was not performed as not relevant in a single arm phase 2 study.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

Methods

- n/a Involved in the study
- Antibodies
- Eukaryotic cell lines
- Palaeontology and archaeology
- Animals and other organisms
- Clinical data
- Dual use research of concern
- Plants

- n/a Involved in the study
- ChIP-seq
- Flow cytometry
- MRI-based neuroimaging

Antibodies

Antibodies used	The antibody panel included FOXP3 (236A/E7, Biocare), programmed death ligand-1 (PD-L1, 1:400, E1L3N, Cell Signaling), CD8 (4B11, 1:500, Leica), PAX8 (EPR18715, 1:1000, Abcam), PD-1 (EPR4877(2), 1:400, Abcam), TOX (E6I3Q, 1:7000, Cell Signaling), as well as 4',6-diamidino-2-phenylindole (DAPI).
Validation	Please see attached document.

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	NCT03241745
Study protocol	The study protocol is provided as a supplementary document with the manuscript submission.
Data collection	This was a single-center, investigator-initiated, single-arm, phase II study conducted at MSK. The study opened to accrual on August 3, 2017. The first patient consented on September 27, 2017, and the final patient on May 24, 2021. The trial has completed as of July 1, 2022.
Outcomes	The co-primary objectives were to define 1) PFS24, and 2) the proportion of patients who achieved objective tumor response (ORR) by RECIST v1.1.1. Secondary objectives included PFS, OS, safety and toxicity, DOR, and DCR. Exploratory objectives were to 1) Correlate the somatic mutational burden with ORR and PFS24; 2) Correlate the somatic mutational burden with MSIsensor score; 3) Correlate MSIsensor score with MMR immunohistochemistry status; 3) Correlate the pre-treatment immune phenotype with ORR and PFS24. Patients were evaluable for efficacy if they had received at least 1 dose of therapy and had at least 1 post-baseline efficacy assessment. Patients who were evaluable for response and were lost to follow-up or died before the 24-week PFS assessment were considered events. PFS was calculated from start of treatment to progression/recurrence or death or last follow-up, whichever occurred first. OS was calculated from start of treatment to death or last follow-up, whichever occurred first. DOR was calculated from time of response (for complete response or partial response) to progression, death, or last follow-up. OS, PFS, and DOR rates were estimated using the Kaplan-Meier method. Adverse events were tabulated. Correlation of response with translational parameters was performed by dichotomizing patients based on PFS24, and distribution of the continuous biomarkers (e.g., percentages of CD8+PD1+ cells) between the 2 groups was compared using Mann-Whitney test. TMBs were compared using the Mann-Whitney test, and comparisons of frequency of mutations were performed using two-tailed Fisher exact tests. For exploratory translational analyses no adjustments for multiple comparisons were performed.

Plants

Seed stocks	<i>Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.</i>
Novel plant genotypes	<i>Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.</i>
Authentication	<i>Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.</i>